Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: Prognostic relevance for late relapse

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Saloustros, Emmanouil ^a   Perraki, Maria ^b   Apostolaki, Stella ^b   Kallergi, Galatea ^b   Xyrafas, Alexandros ^a   Kalbakis, Kostas ^a   Agelaki, Sophia ^a   Kalykaki, Antonia ^a   Georgoulias, Vassilis ^a,b   Mavroudis, Dimitris ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 19; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; ADULT; AGED; BLOOD; BREAST TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR EMBOLISM; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-19; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79958181044     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2897     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, . Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792. 10.1056/NEJMoa050518, 16251534, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
3. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 2005, 89:173-178. 10.1007/s10549-004-1722-0, 15692760.
4. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991, 9:1650-1661.
5. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
7. Bonadonna G, Moliterni A, Zambett M, Stefanelli M, Cipriani S, Valagussa P, Bonadonna G, Gianni L. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005, 330:217-220. 10.1136/bmj.38314.622095.8F, 546063, 15649903.
8. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. 10.1056/NEJMoa050434, 16120859.
9. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999, 91:1113-1124. 10.1093/jnci/91.13.1113, 10393719.
10. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 2002, 20:3404-3412. 10.1200/JCO.2002.08.135, 12177100.
11. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006, 24:3756-3762. 10.1200/JCO.2005.04.5948, 16769987.
12. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005, 92:906-912. 10.1038/sj.bjc.6602418, 2361897, 15714202.
13. Brown NM, Stenzel TT, Friedman PN, Henslee J, Huper G, Marks JR. Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Res Treat 2006, 97:41-47. 10.1007/s10549-005-9085-8, 16319979.
14. Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, Georgoulias V. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 2003, 23:1883-1890.
15. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003, 14:849-855. 10.1093/annonc/mdg259, 12796021.
16. Quintela-Fandino M, Lopez JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy and peripheral blood stem cell support. J Clin Oncol 2006, 24:3611-3618. 10.1200/JCO.2005.04.0576, 16877728.
17. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients with Early Breast Cancer. J Clin Oncol 2009, 27:2177-2184. 10.1200/JCO.2008.18.0497, 19332733.
18. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavourable clinical outcome. Clin Cancer Res 2004, 10:5342-5348. 10.1158/1078-0432.CCR-04-0245, 15328170.
19. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005, 103:884-891. 10.1002/cncr.20834, 15666325.
20. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the LightCycler system. Clin Cancer Res 2003, 9:5145-5151.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
22. Saloustros E, Mavroudis D. Cytokeratin-19 positive circulating tumor cells in early breast cancer prognosis. Future Oncol 2010, 6:209-219. 10.2217/fon.09.147, 20146580.
23. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, Höffken K. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008, 26:1208-1215. 10.1200/JCO.2007.13.6523, 18323545.
24. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B, Nap M, Jörnvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999, 187:567-572. 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J, 10398123.
25. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997, 138:1379-1394. 10.1083/jcb.138.6.1379, 2132555, 9298992.
26. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
27. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
28. Rack B, Schindlbeck C, Andergassen U, Lorentz R, Zwingers T, Schneeweiss A, Lichtenegger W, Bechmann MW, Sommer H, Pantel K, Friese K, Janni W, . for the SUCCESS Study Group Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer. Cancer Res 2010, (suppl):93s. for the SUCCESS Study Group.
29. Alix-Panabieres C, Sabine Riethdorf S, Pantel K. circulatingtumor cells and bone marrow micrometastasis. Clin Cancer Res 2008, 14:5013-5021. 10.1158/1078-0432.CCR-07-5125, 18698019.
30. Riethdorf S, Mueller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Houber J, Fehm T, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and Her-2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neo-adjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
31. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 2007, 13:79-88. 1869618, 17515959.